Angus M. Brown

Dr. Angus M. Brown


Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2007 in Glia
Verified
Journal Article
Closed access
PDF file
ABAngus M. Brown
Angus M. Brown
BRBruce R. Ransom
Bruce R. Ransom

1 June 2001 in Computer Methods and Programs in Biomedicine
Verified
Journal Article
Closed access
ABAngus M. Brown
Angus M. Brown

15 September 2000 in Journal of Neuroscience
Verified
Journal Article
Closed access
RWRegina Wender
Regina Wender
ABAngus M. Brown
Angus M. Brown
Robnert FernRobnert Fern
Robnert Fern
RSRaymond A. Swanson
Raymond A. Swanson
KFKevin Farrell
Kevin Farrell
BRBruce R. Ransom
Bruce R. Ransom
We tested the hypothesis that astrocytic glycogen sustains axon function during and enhances axon survival after 60 min of glucose deprivation. Axon function in the rat optic nerve (RON), a CNS white matter tract, was monitored by measuring the area of the stimulus-evoked compound action potential (CAP). Switching to glucose-free artificial CSF (aCSF) had no effect on the CAP area for ∼30 min, after which the CAP rapidly failed. Exposure to glucose-free aCSF for 60 min caused irreversible injury, which was measured as incomplete recovery of the CAP. Glycogen content of the RON fell to a low stable level 30 min after glucose withdrawal, compatible with rapid use in the absence of glucose. An increase of glycogen content induced by high-glucose pretreatment increased the latency to CAP failure and improved CAP recovery. Conversely, a decrease of glycogen content induced by norepinephrine pretreatment decreased the latency to CAP failure and reduced CAP recovery. To determine whether lactate represented the fuel derived from glycogen and shuttled to axons, we used the lactate transport blockers quercetin, α-cyano-4-hydroxycinnamic acid (4-CIN), andp-chloromercuribenzene sulfonic acid (pCMBS). All transport blockers, when applied during glucose withdrawal, decreased latency to CAP failure and decreased CAP recovery. The inhibitors 4-CIN and pCMBS, but not quercetin, blocked lactate uptake by axons. These results indicated that, in the absence of glucose, astrocytic glycogen was broken down to lactate, which was transferred to axons for fuel.

30 March 2004 in Journal of Neurochemistry
Verified
Journal Article
Closed access
PDF file
ABAngus M. Brown
Angus M. Brown

13 July 2005 in Journal of Neuroscience Research
Verified
Journal Article
Closed access
PDF file
STSelva Baltan Tekkök
Selva Baltan Tekkök
ABAngus M. Brown
Angus M. Brown
RWRuth Westenbroek
Ruth Westenbroek
LPLuc Pellerin
Luc Pellerin
BRBruce R. Ransom
Bruce R. Ransom

1 June 2003 in The Journal of Physiology
Verified
Journal Article
Open access
PDF file
ABAngus M. Brown
Angus M. Brown
STSelva Baltan Tekkök
Selva Baltan Tekkök
BRBruce R. Ransom
Bruce R. Ransom
CNS glycogen, contained predominantly in astrocytes, can be converted to a monocarboxylate and transported to axons as an energy source during aglycaemia. We analysed glycogen regulation and the role of glycogen in supporting neural activity in adult mouse optic nerve, a favourable white matter preparation. Axon function was quantified by measuring the compound action potential (CAP) area. During aglycaemia, axon function persisted for 20 min, then declined in conjunction with glycogen content. Lactate fully supported CAPs in the absence of glucose, but was unable to sustain glycogen content; thus, axon failure occurred rapidly when lactate was withdrawn. Glycogen content in the steady state was directly proportional to bath glucose concentration. Increasing [K+]o to 10 mm caused a rapid decrease in glycogen content. Latency to onset of CAP failure during aglycaemia was directly proportional to glycogen content and varied from about 2 to 30 min. Intense neural activity reduced glycogen content in the presence of 10 mm bath glucose and CAP area gradually declined. CAP area declined more rapidly during high frequency stimulation if monocarboxylate transport was inhibited. This suggested that astrocytic glycogen was broken down to a monocarboxylate(s) that was used by rapidly discharging axons. Likewise, depleting glycogen by brief periods of high frequency axon stimulation accelerated onset of CAP decline during aglycaemia. In summary, these experiments indicated that glycogen content was under dynamic control and that glycogen was used to support the energy needs of CNS axons during both physiological as well as pathological processes.